MEDIGENE NA O.N. KONV. Forum: Community User: gordon_gekko

530684, na MG pendelt schon seit geraumer Zeit zwischen 5,20 und 6,30. Für mich ist hier der Boden gefunden, nur m.M. 5,20 ist auch als starker Widerstand zu sehen.

Baader Bank belässt Medigene auf 'Hold' - Ziel 11 Euro MÜNCHEN (dpa-AFX Analyser) - Die Baader Bank hat die Einstufung für Medigene nach Zahlen auf "Hold" mit einem Kursziel von 11 Euro belassen. Analyst Bruno Bulic stellt in einer am Mittwoch vorliegenden Studie ein Fragezeichen hinter die klinische Erprobung der TCR-Immuntherapie MDG1011 gegen Blutkrebserkrankungen. Es ist ihm nicht klar, wie der Wirkstoffforscher die Studie mit dem aktuellen Tempo wie geplant bis April 2024 abschließen will./ag/jha Veröffentlichung der Original-Studie: 13.11.2019 / 08:25 / CET Erstmalige Weitergabe der Original-Studie: 13.11.2019 / 08:25 / CET Hinweis: Informationen zur Offenlegungspflicht bei Interessenkonflikten im Sinne von § 85 Abs. 1 WpHG, Art. 20 VO (EU) 596/2014 für das genannte Analysten-Haus finden Sie unter http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html. Quelle: BAADER BANK

https://seekingalpha.com/article/4306126-medigene-ag-2019-q3-results-earnings-call-presentation

Nein

kommt die 4,xx Euro ??

https://www.finanznachrichten.de/nachrichten-2019-11/48161607-irw-news-medigene-ag-medigene-berichtet-ueber-finanz-und-geschaeftsergebnisse-fuer-die-ersten-neun-monate-2019-016.htm

Autsch. Die Pressekonferenz zum Quartal wird keine Freude machen.

Der Text vermittelt aber schon, dass man den richtigen Ansatz hat. Später kommen dann noch die Feineinstellungen.

Erste Ergebnisse aus Phase 2 Nantkwest Natural Killer Cell Therapie: 2 von 7 ist aber auch noch kein Grund zu jubeln... Mal abwarten ist erst Phase 2 NantKwest Announces Presentation of Positive Phase 2 Clinical Data of Natural Killer Cell Therapy in Metastatic Merkel Cell Carcinoma at SITC 2019 Durable Responses Demonstrated in 2 of 7 Patients with Refractory Metastatic MCC Data Supportive of Planned Off-the-Shelf Clinical Trial to Confirm Activity and Safety November 07, 2019 04:15 PM Eastern Standard Time CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, today announced the presentation of results from their Phase 2 trial investigation using aNK, NantKwest’s off-the-shelf natural killer cell-based therapeutic, in combination with N-803, ImmunityBio’s IL-15 superagonist, in patients with advanced refractory metastatic Merkel cell carcinoma (MCC) (NCT03853317) at The 34th Annual Meeting of the Society for Immunotherapy for Cancer (SITC 2019) on November 8, 2019 in National Harbor, Maryland. ImmunityBio is an affiliate company of NantKwest. “We believe the results of this Phase 2 study are testament to the potential of our natural killer cell-based therapeutics to change the cancer treatment paradigm” Dr. Shailender Bhatia, Associate Professor of Medical Oncology at the University of Washington/Fred Hutchinson Cancer Research Center, will make an oral presentation entitled “Final results from a phase 2 study using off-the-shelf activated natural killer (aNK) cells in combination with N-803, an IL-15 superagonist, in patients with metastatic Merkel cell carcinoma (MCC).” That study demonstrated long term, durable responses in 2 of 7 patients with advanced refractory MCC. One of these patients achieved a radiologic complete response, and the second a durable partial response with more than 75% tumor regression and no subsequent therapy (response ongoing to date). Both patients with responses in the trial remain alive to date, 29 and 44 months after the initiation of treatment. Results from this study provide evidence that treatment with aNK cell therapy can stimulate immune responses to checkpoint inhibitors, even in patients that have previously failed treatments using these types of therapies. One heavily pretreated subject refractory to pembrolizumab was rechallenged with this checkpoint inhibitor subsequent to receiving aNK cell therapy resulting in a durable complete response (CR) that is ongoing at this time, 44 months after receipt of first aNK cell infusion. “We believe the results of this Phase 2 study are testament to the potential of our natural killer cell-based therapeutics to change the cancer treatment paradigm,” said Dr. Patrick Soon-Shiong, Chairman and CEO of NantKwest. “Long term responses in patients with refractory metastatic disease is a remarkable achievement and is supportive of our upcoming trial, which will evaluate NantKwest’s off-the-shelf CD16-targeted haNK cells in combination with N-803 and Pfizer’s avelumab in patients with advanced MCC who are refractory to immune checkpoint inhibitors. We are particularly enthusiastic about the potential of aNK and N-803 to induce sensitization to checkpoint inhibitors, and thus, are evaluating this in our upcoming trial. We remain deeply committed to harnessing the power of immunogenic cell death across a wide range of indications to provide innovative treatments to patients with serious unmet need.” Other presentation highlights include: Overall response rate of 29% (2 of 7 patients) Evidence that aNK cell treatment may induce sensitivity to immune checkpoint inhibitors with a patient previously refractory to pembrolizumab demonstrating an ongoing complete response to the checkpoint inhibitor after completing aNK cell therapy aNK cell therapy resulted in increased levels of tumor-infiltrating lymphocytes and increased immune response-related gene expression within tumor tissue aNK cells in combination with N-803 were well-tolerated, with no treatment-related serious adverse events or grade ≥3 adverse events Infusions all safely administered in the outpatient setting without observed immune related adverse events Dr. Bhatia said, “Merkel cell carcinoma (MCC) is an aggressive skin cancer that is estimated to be three times more deadly than melanoma. PD-1 blockade works well for around 50 percent of patients with metastatic disease, but a significant proportion do not respond or progress later. Innate immunotherapy approach using aNK cells can potentially overcome resistance mechanisms in PD-1 refractory tumors. I am particularly enthusiastic about the preliminary results of the MCC study, with two complete responses in patients with very advanced metastatic disease.”

Ob wir die 18 Euro noch mal sehen werden ?

Ich warte noch.. Könnte sich jetzt allerdings ein Boden bilden.. Wäre aber erst ab 4 bereit richtig zuzuschlagen

@Monokelchen Bin noch Jungfuchs in Sachen Aktien. Kannst Du mich mal aufgleisen was bedeutet der Stopp? Bin zur Zeit mit ca. 55% in den Miesen, von daher momentan nicht so lustig!

530684, schon bemerkt, dass es hier nen Stopp gegeben hat.? Morgen kommen Quartalszahlen. Der wichtigere Termin dürfte allerdings der 07 bis 10.12.19 sein, da will MG erste Daten aus DC Vakzine präsentieren.

Also ich bin hier investiert und werde abwarten

Hier gehts nur noch abwärts.

Wann bewegt sich hier nach oben ?